LIXTE Biotechnology Holdings, Inc. Regains Compliance With Nasdaq Continued Listing Requirements
Portfolio Pulse from Benzinga Newsdesk
LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share and meets all other criteria for continued listing. The company effected a 1-for-10 reverse stock split to address the issue.
June 23, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LIXTE Biotechnology's stock regains compliance with Nasdaq's minimum bid price requirement after a 1-for-10 reverse stock split.
LIXTE Biotechnology's stock regaining compliance with Nasdaq's minimum bid price requirement is a positive development for the company. The 1-for-10 reverse stock split helped the company meet the requirement, which could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100